Препарат LY2140023 не превзошел по эффективности плацебо

Eli Lilly (LLY) announced Wednesday that its schizophrenia drug candidate didn't do better than the placebo in a phase-two study.

The study in question looked at the drug, called pomaglumetad methionil, as the sole treatment for the mental disease, but another ongoing trial is still studying the compound as a supplemental treatment with other medicines. Lilly said that trial is complete, but it's still awaiting results.

 Lilly's Schizophrenia Drug Candidate Fails Trial